(Q34167899)

31 July 2017

1 reference

title

Adverse effects of long-term proton pump inhibitor therapy (English)

1 reference

31 July 2017

George Triadafilopoulos

series ordinal

2

object named as

George Triadafilopoulos

0 references

author name string

Edward Sheen

series ordinal

1

1 reference

31 July 2017

2 March 2011

1 reference

Digestive Diseases and Sciences

31 July 2017

1 reference

31 July 2017

56

1 reference

31 July 2017

4

1 reference

31 July 2017

931-950

1 reference

https://scigraph.springernature.com/pub.10.1007/s10620-010-1560-3

31 July 2017

0 references

cites work

A meta-analysis comparing the efficacy of omeprazole with H2-receptor antagonists for acute treatment of duodenal ulcer in Asian patients

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1560-3

Proton pump inhibitors versus H2-antagonists: a meta-analysis of their efficacy in treating bleeding peptic ulcer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1560-3

Meta-analysis: proton pump inhibitors vs. H2-receptor antagonists--their efficacy with antibiotics in Helicobacter pylori eradication

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1560-3

Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1560-3

Guidelines for prevention of NSAID-related ulcer complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1560-3

Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1560-3

Long-term safety concerns with proton pump inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1560-3

Association of long-term proton pump inhibitor therapy with bone fractures and effects on absorption of calcium, vitamin B12, iron, and magnesium

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1560-3

The burden of selected digestive diseases in the United States.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1560-3

Effect of long-term gastric acid suppressive therapy on serum vitamin B12 levels in patients with Zollinger-Ellison syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1560-3

Do acid-lowering agents affect vitamin B12 status in older adults?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1560-3

A case-control study on adverse effects: H2 blocker or proton pump inhibitor use and risk of vitamin B12 deficiency in older adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1560-3

Long-term use of proton pump inhibitors and vitamin B12 status in elderly individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1560-3

Vitamin B12 deficiency in hypersecretors during long-term acid suppression with proton pump inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1560-3

Vitamin B(12) deficiency is linked with long-term use of proton pump inhibitors in institutionalized older adults: could a cyanocobalamin nasal spray be beneficial?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1560-3

Vitamin B12 levels during prolonged treatment with proton pump inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1560-3

Effect of omeprazole on oral iron replacement in patients with iron deficiency anemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1560-3

Proton pump inhibitors suppress absorption of dietary non-haem iron in hereditary haemochromatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1560-3

Effect of proton pump inhibitors on vitamins and iron

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1560-3

Severe hypomagnesaemia in long-term users of proton-pump inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1560-3

Proton pump inhibitors and severe hypomagnesaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1560-3

Chronic use of proton-pump inhibitors associated with giardiasis: A rare cause of hypomagnesemic hypoparathyroidism?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1560-3

A case series of proton pump inhibitor-induced hypomagnesemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1560-3

Hypomagnesaemia due to proton-pump inhibitor therapy: a clinical case series

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1560-3

Severe hypomagnesemia during long-term treatment with a proton pump inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1560-3

Omeprazole and refractory hypomagnesaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1560-3

Recent developments in intestinal magnesium absorption

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1560-3

Functional characterization of homo- and heteromeric channel kinases TRPM6 and TRPM7

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1560-3

Esomeprazole induces upper gastrointestinal tract transmucosal permeability increase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1560-3

Alteration in digestion and absorption of nutrients during profound acid suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1560-3

Gastrointestinal absorption of calcium from milk and calcium salts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1560-3

Regulation of vitamin D and calcium metabolism after gastrectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1560-3

The Absorption of Calcium Carbonate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1560-3

Effect of omeprazole, an inhibitor of H+,K(+)-ATPase, on bone resorption in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1560-3

Hypochlorhydria from short-term omeprazole treatment does not inhibit intestinal absorption of calcium, phosphorus, magnesium or zinc from food in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1560-3

Effects of proton pump inhibitors on calcium carbonate absorption in women: a randomized crossover trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1560-3

An evaluation of the importance of gastric acid secretion in the absorption of dietary calcium

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1560-3

Bone mineral density in patients taking H2-receptor antagonist.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1560-3

Acid-suppressive medications and risk of bone loss and fracture in older adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1560-3

Hip fracture risk in patients with a diagnosis of pernicious anemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1560-3

Long-term proton pump inhibitor therapy and risk of hip fracture

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1560-3

Use of proton pump inhibitors and risk of osteoporosis-related fractures

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1560-3

Proton pump inhibitors and histamine-2 receptor antagonists are associated with hip fractures among at-risk patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1560-3

Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1560-3

Non-Helicobacter pylori bacterial flora during acid-suppressive therapy: differential findings in gastric juice and gastric mucosa.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1560-3

Suppression of gastric acid secretion in patients with gastroesophageal reflux disease results in gastric bacterial overgrowth and deconjugation of bile acids

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1560-3

Bacterial overgrowth during treatment with omeprazole compared with cimetidine: a prospective randomised double blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1560-3

Omeprazole treatment diminishes intra- and extracellular neutrophil reactive oxygen production and bactericidal activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1560-3

Occurrence of community-acquired respiratory tract infection in patients receiving esomeprazole: retrospective analysis of adverse events in 31 clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1560-3

Gastric acid‐suppressive therapy and community‐acquired respiratory infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1560-3

Proton-pump inhibitor use and the risk for community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1560-3

Use of proton pump inhibitors and H2 blockers and risk of pneumonia in older adults: a population-based case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1560-3

EFFECT OF CIMETIDINE ON THE GASTRIC BACTERIAL FLORA

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1560-3

Relationship between gastric secretion and infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1560-3

Influence of gastric pH on gastric and jejunal flora

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1560-3

Effect of omeprazole on intragastric bacterial counts, nitrates, nitrites, and N-nitroso compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1560-3

Duodenal bacterial overgrowth during treatment in outpatients with omeprazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1560-3

The pharmacovigilance of pantoprazole: the results of postmarketing surveillance on 11 541 patients in England

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1560-3

The rates of common adverse events reported during treatment with proton pump inhibitors used in general practice in England: cohort studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1560-3

A prospective follow-up study of 5669 users of lansoprazole in daily practice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1560-3

Characteristics of diarrhoea in 10,008 users of lansoprazole in daily practice: which co-factors contribute?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1560-3

Gastric acid, acid-suppressing drugs, and bacterial gastroenteritis: how much of a risk?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1560-3

Omeprazole as a risk factor for campylobacter gastroenteritis: case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1560-3

Novel insight in the association between salmonellosis or campylobacteriosis and chronic illness, and the role of host genetics in susceptibility to these diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1560-3

Recent treatment with H2 antagonists and antibiotics and gastric surgery as risk factors for Salmonella infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1560-3

Use of acid-suppressing drugs and the risk of bacterial gastroenteritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1560-3

Risk factors for Salmonella Enteritidis and Typhimurium (DT104 and non-DT104) infections in The Netherlands: predominant roles for raw eggs in Enteritidis and sandboxes in Typhimurium infections.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1560-3

Therapy with gastric acidity inhibitors increases the risk of acute gastroenteritis and community-acquired pneumonia in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1560-3

Systematic review of the risk of enteric infection in patients taking acid suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1560-3

Gastric acid secretion and enteric infection in Bangladesh

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1560-3

An outbreak of type 4b Listeria monocytogenes infection involving patients from eight Boston hospitals

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1560-3

Proton-pump inhibition and gastric giardiasis: a causal or casual association?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1560-3

Another example of Strongyloides stercoralis infection associated with cimetidine in an immunosuppressed patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1560-3

Strongyloides stercoralis hyperinfection associated with cimetidine in an immunosuppressed patient: diagnosis by endoscopic biopsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1560-3

Gastric juice: a barrier against infectious diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1560-3

Antibiotics and hospital-acquired Clostridium difficile-associated diarrhoea: a systematic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1560-3

Proton pump inhibitor use and enteric infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1560-3

A case-control study of community-associated Clostridium difficile infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1560-3

Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1560-3

Proton pump inhibitors and gastric neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1560-3

Review article: potential gastrointestinal effects of long-term acid suppression with proton pump inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1560-3

Hypergastrinaemia during long-term omeprazole therapy: influences of vagal nerve function, gastric emptying and Helicobacter pylori infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1560-3

Rebound hypersecretion after omeprazole and its relation to on-treatment acid suppression and Helicobacter pylori status.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1560-3

Proton-pump inhibitor therapy induces acid-related symptoms in healthy volunteers after withdrawal of therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1560-3

Rebound acid hypersecretion from a physiological, pathophysiological and clinical viewpoint

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1560-3

Fundic gland polyps in familial adenomatous polyposis: neoplasms with frequent somatic adenomatous polyposis coli gene alterations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1560-3

Incidence of fundic gland polyps in patients without familial adenomatous polyposis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1560-3

Gastric polyps: an update of their pathology and biological significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1560-3

Parietal cell protrusions and fundic gland cysts during omeprazole maintenance treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1560-3

Low prevalence of Helicobacter pylori infection in patients with hamartomatous fundic polyps

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1560-3

Spontaneous resolution of multiple fundic gland polyps after cessation of treatment with lansoprazole and Nissen fundoplication: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1560-3

Fundic gland polyps are not induced by proton pump inhibitor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1560-3

Sporadic fundic gland polyps: common gastric polyps arising through activating mutations in the beta-catenin gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1560-3

Dysplasia in fundic gland polyps is associated with nuclear beta-catenin expression and relatively high cell turnover rates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1560-3

Sporadic fundic gland polyposis: a clinical, histological, and molecular analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1560-3

Sporadic fundic gland polyps with epithelial dysplasia : evidence for preferential targeting for mutations in the adenomatous polyposis coli gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1560-3

Altered cellular distribution of tuberin and glucocorticoid receptor in sporadic fundic gland polyps

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1560-3

Gastric polyps in pediatrics: an 18-year hospital-based analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1560-3

Gastric cancer risk in achlorhydric patients. A long-term follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1560-3

Cancer after peptic ulcer surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1560-3

Mortality from gastric cancer following gastric surgery for peptic ulcer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1560-3

Clinical significance of hypergastrinaemia: relevance to gastrin monitoring during omeprazole therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1560-3

Intestinal metaplasia of the stomach. A status report

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1560-3

A H+-gated urea channel: the link between Helicobacter pylori urease and gastric colonization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1560-3

Changes in the intragastric distribution of Helicobacter pylori during treatment with omeprazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1560-3

Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1560-3

Changes of gastric mucosal architecture during long-term omeprazole therapy: results of a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1560-3

Helicobacter pylori infection and the development of gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1560-3

American College of Gastroenterology guideline on the management of Helicobacter pylori infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1560-3

A 5-decade analysis of 13,715 carcinoid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1560-3

Gastric carcinoids: a temporal increase with proton pump introduction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1560-3

Antiulcer drugs and gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1560-3

Review article: current perspectives on hypergastrinaemia and enterochromaffin-like-cell hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1560-3

Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1560-3

Gastric endocrine cells and gastritis in patients receiving long-term omeprazole treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1560-3

Association of long lasting unsurmountable histamine H2 blockade and gastric carcinoid tumours in the rat

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1560-3

Effects of antrectomy or porta-caval shunting on the histamine-storing endocrine-like cells in oxyntic mucosa of rat stomach. A fluorescence histochemical, electron microscopic and chemical study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1560-3

Endocrine cells in the human oxyntic mucosa. A histochemical study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1560-3

Rectal cell proliferation and colon cancer risk in patients with hypergastrinaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1560-3

Gastrin and colorectal cancer: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1560-3

Chronic proton pump inhibitor therapy and the risk of colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1560-3

Proton pump inhibitor use and risk of colorectal cancer: a population-based, case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1560-3

Proton pump inhibitors and the risk of colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1560-3

A summary of Food and Drug Administration-reported adverse events and drug interactions occurring during therapy with omeprazole, lansoprazole and pantoprazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1560-3

Pharmacokinetic drug interaction profiles of proton pump inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1560-3

Proton pump inhibitors: an update of their clinical use and pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1560-3

Effect of proton pump inhibitors on serum thyroid-stimulating hormone level in euthyroid patients treated with levothyroxine for hypothyroidism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1560-3

Gastric acid-reducing medications and clopidogrel: what are the latest FDA recommendations?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1560-3

Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1560-3

Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1560-3

Cardiovascular outcomes and mortality in patients using clopidogrel with proton pump inhibitors after percutaneous coronary intervention or acute coronary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1560-3

Outcomes with concurrent use of clopidogrel and proton-pump inhibitors: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1560-3

Risk of rehospitalization for patients using clopidogrel with a proton pump inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1560-3

Cytochrome p-450 polymorphisms and response to clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1560-3

The safety of proton pump inhibitors in pregnancy: a multicentre prospective controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1560-3

Use of omeprazole during pregnancy--no hazard demonstrated in 955 infants exposed during pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1560-3

The safety of proton pump inhibitors in pregnancy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1560-3

Use of proton pump inhibitors during pregnancy and rates of major malformations: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1560-3

Use of proton-pump inhibitors in early pregnancy and the risk of birth defects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1560-3

First evidence of a possible association between gastric acid suppression during pregnancy and childhood asthma: a population-based register study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1560-3

Proton-Pump Inhibitor Use Is Not Associated With Osteoporosis or Accelerated Bone Mineral Density Loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1560-3

Proton Pump Inhibitor Use and Risk of Hip Fractures in Patients without Major Risk Factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10620-010-1560-3

Lansoprazole and omeprazole have similar effects on plasma gastrin levels, enterochromaffin-like cells, gastrin cells and somatostatin cells in the rat stomach

21 January 2018

1 reference

12 December 2020

Effects of esomeprazole on acid output in patients with Zollinger-Ellison syndrome or idiopathic gastric acid hypersecretion

1 reference

12 December 2020

Twenty-four-hour intragastric pH profiles and pharmacokinetics following single and repeated oral administration of the proton pump inhibitor pantoprazole in comparison to omeprazole

1 reference

12 December 2020

Role of gastric acid in food iron absorption

1 reference

12 December 2020

Ascorbic acid chelates in iron absorption: a role for hydrochloric acid and bile

1 reference

12 December 2020

Pharmacology and toxicology of omeprazole--with special reference to the effects on the gastric mucosa

1 reference

12 December 2020

Hypomagnesaemia due to use of proton pump inhibitors--a review

1 reference

12 December 2020

Effect of L-lactic acid on calcium absorption in rats fed omeprazole

1 reference

12 December 2020

Long-term use of proton pump inhibitors does not affect the frequency, growth, or histologic characteristics of colon adenomas

1 reference

12 December 2020

Gastroesophageal reflux symptoms during and after pregnancy: a longitudinal study

1 reference

12 December 2020

Cobalamin deficiency with megaloblastic anaemia in one patient under long-term omeprazole therapy

1 reference

12 December 2020

Effect of short- and long-term treatment with omeprazole on the absorption and serum levels of cobalamin

1 reference

12 December 2020

Bacterial overgrowth as a consequence of reduced gastric acidity

1 reference

12 December 2020

Drug-induced changes of plasma gastrin concentration

1 reference

12 December 2020

Fundic gland polyps: three other case reports suggesting a possible association with acid suppressing therapy

1 reference

12 December 2020

Review article: infective complications of therapeutic gastric acid inhibition.

1 reference

12 December 2020

The in vitro growth response of primary human colorectal and gastric cancer cells to gastrin

1 reference

12 December 2020

Frequent CpG island methylation in sporadic and syndromic gastric fundic gland polyps.

1 reference

12 December 2020

Review article: metabolic consequences of long-term inhibition of acid secretion by omeprazole

1 reference

12 December 2020

Rabeprazole: pharmacokinetics and pharmacokinetic drug interactions.

1 reference

12 December 2020

An unknown but potentially serious side effect of proton pump inhibitors: hypomagnesaemia

1 reference

12 December 2020

Risk factors for reduced bone density in haemodialysis patients

1 reference

12 December 2020

The importance of gastric hydrochloric acid in the absorption of nonheme food iron

1 reference

12 December 2020

A new mechanism for anti-inflammatory actions of proton pump inhibitors--inhibitory effects on neutrophil-endothelial cell interactions

1 reference

12 December 2020

Inhibition of iron absorption by omeprazole in rat model

1 reference

12 December 2020

Proton pump inhibitors, histamine H2 receptor antagonists, and other antacid medications and the risk of fracture

1 reference

12 December 2020

Low gastric hydrochloric acid secretion and mineral bioavailability.

1 reference

12 December 2020

Use of proton pump inhibitors and the risk of community-acquired pneumonia: a population-based case-control study

1 reference

12 December 2020

A study on the relation between proton pump inhibitor and gastric giardiasis

1 reference

12 December 2020

Risk of fractures in patients with pernicious anemia

1 reference

12 December 2020

Increase of Helicobacter pylori-associated corpus gastritis during acid suppressive therapy: implications for long-term safety

1 reference

12 December 2020

Neutropenia associated with omeprazole

1 reference

12 December 2020

Effect of cimetidine on the gastric bacterial flora

1 reference

12 December 2020

Proton pump inhibitor-associated gastric polyps: a retrospective analysis of their frequency, and endoscopic, histologic, and ultrastructural characteristics

1 reference

12 December 2020

Conflicting evidence surrounding the clopidogrel and proton pump inhibitor drug interaction

1 reference

12 December 2020

Omeprazole and H2-receptor antagonists in the acute treatment of duodenal ulcer, gastric ulcer and reflux oesophagitis: a meta-analysis.

1 reference

12 December 2020

Population dynamics of ingested Clostridium difficile in the gastrointestinal tract of the Syrian hamster

1 reference

12 December 2020

The safety of proton pump inhibitors (PPIs) in pregnancy: a meta-analysis

1 reference

12 December 2020

Omeprazole, a specific inhibitor of H+-K+-ATPase, inhibits bone resorption in vitro

1 reference

12 December 2020

Lack of effect of acid suppression therapy on gastric atrophy. Nordic Gerd Study Group

1 reference

12 December 2020

Gastric endocrine cells in omeprazole-treated and untreated patients with the Zollinger-Ellison syndrome

1 reference

12 December 2020

Severe Clostridium difficile-associated disease in populations previously at low risk--four states, 2005.

1 reference

12 December 2020

Omeprazole and fundic gland polyps

1 reference

12 December 2020

Delivery outcome after the use of acid-suppressing drugs in early pregnancy with special reference to omeprazole

1 reference

12 December 2020

The effect of omeprazole on human natural killer cell activity

1 reference

12 December 2020

Use of cimetidine, omeprazole, and ranitidine in pregnant women and pregnancy outcomes

1 reference

12 December 2020

Alteration of normal gastric flora in neonates receiving ranitidine

1 reference

12 December 2020

Nutritional and pharmaceutical aspects of calcium supplementation

1 reference

12 December 2020

Omeprazole produces parietal cell hypertrophy and hyperplasia in humans

1 reference

12 December 2020

Frequency, location, and age and sex distribution of various types of gastric polyp

1 reference

12 December 2020

Hypomagnesemia induced by several proton-pump inhibitors

1 reference

12 December 2020

Are there three types of Helicobacter pylori gastritis?

1 reference

12 December 2020

Gastric polyposis: onset during long-term therapy with omeprazole

1 reference

12 December 2020

The safety of omeprazole during pregnancy: A multicenter prospective controlled study

1 reference

12 December 2020

Proton pump inhibitors and hospitalization for Clostridium difficile-associated disease: a population-based study

1 reference

12 December 2020

Histamine enhances interleukin (IL)-1-induced IL-6 gene expression and protein synthesis via H2 receptors in peripheral blood mononuclear cells

1 reference

12 December 2020

Qualitative studies of gastric endocrine cells in patients treated long-term with omeprazole

1 reference

12 December 2020

Intrinsic Factor Secretion and Cobalamin Absorption: Physiology and Pathophysiology in the Gastrointestinal Tract

1 reference

12 December 2020

Proton-pump inhibitors and hypomagnesemic hypoparathyroidism

1 reference

12 December 2020

Helicobacter colonization and histopathological profile of chronic gastritis in patients with or without dyspepsia, mucosal erosion and peptic ulcer: a morphological approach to the study of ulcerogenesis in man

1 reference

12 December 2020

Infective gastroenteritis and its relationship to reduced gastric acidity

1 reference

12 December 2020

Three subtypes of gastric argyrophil carcinoid and the gastric neuroendocrine carcinoma: a clinicopathologic study

1 reference

12 December 2020

Fundic gland polyps: a rare, innocuous, and reversible disturbance

1 reference

12 December 2020

Effect of L-lactic acid on the absorption of calcium in gastrectomized rats

1 reference

12 December 2020

Intragastric bacterial activity and nitrosation before, during, and after treatment with omeprazole

1 reference

12 December 2020

Gastric endocrine cell hyperplasia and carcinoid tumors in pernicious anemia

1 reference

12 December 2020

Fundic gland polyps developing during omeprazole therapy

1 reference

12 December 2020

Observation of gastric glandular cysts in the corpus mucosa of the stomach under omeprazole treatment

1 reference

12 December 2020

Increased risk of fundic gland polyps during long-term proton pump inhibitor therapy

1 reference

12 December 2020

Partial gastric corpectomy results in hypergastrinemia and development of gastric enterochromaffinlike-cell carcinoids in the rat.

1 reference

12 December 2020

10.1007/S10620-010-1560-3

Identifiers

DOI

1 reference

PubMed ID

21365243

Dimensions Publication ID

31 July 2017

0 references

1 reference

PubMed ID

21365243